8
Participants
Start Date
November 30, 2004
Primary Completion Date
April 30, 2006
Study Completion Date
December 31, 2006
EM-1421
EM-1421 administered intravaginally every 3 weeks as 45 mg (1% w/w) EM-1421 or 90 mg (2% w/w) EM-1421
University of Maryland, Dept. of Family Medicine, Baltimore
Lead Sponsor
University of Maryland, Baltimore County
OTHER
Planned Parenthood Delaware (Wilmington, DE)
UNKNOWN
Erimos Pharmaceuticals
INDUSTRY